Literature DB >> 8929623

Neonatal changes of osteoclasts in osteopetrosis (op/op) mice defective in production of functional macrophage colony-stimulating factor (M-CSF) protein and effects of M-CSF on osteoclast development and differentiation.

S Umeda1, K Takahashi, M Naito, L D Shultz, K Takagi.   

Abstract

In mice homozygous for the osteopetrosis (op) mutation, loss of osteoclasts in the postnatal period and their development, differentiation, and maturation following daily M-CSF administration in adult life were investigated. Histochemical, immunohistochemical, and ultrastructural approaches, as well as [3H]thymidine autoradiography, clarified the role of M-CSF on osteoclast development and differentiation. In op/op mice osteoclasts appeared normal at birth. However, osteoclast numbers were reduced within a few days after birth, and osteoclasts were undetectable by 3-4 days of age. In adult op/op mice there were no multinuclear osteoclasts; however, small numbers of mononuclear cells (so-called 'preosteoclasts') were observed on the endosteal surface of bone. These preosteoclasts expressed tartrate-resistant acid phosphatase and showed ultrastructural features of immature osteoclasts. After daily M-CSF administration in op/op mice, osteoclasts developed from the fusion of preosteoclasts and osteoclasts numbers increased to the levels of normal littermates at 3 days. Autoradiographic analysis with [3H]thymidine revealed no labeling in osteoclasts and preosteoclasts. In the mutant mice, M-CSF administration induced numerical increases of monocytes, promonocytes, and earlier precursor cells in bone marrow, ER-MP12- or, ER-MP58-positive granulocyte/macrophage colony-forming cells (GM-CFCs). Among these macrophage precursors, ER-MP58-positive cells were considered preosteoclast precursors, and possessed marked proliferative potential. These data suggest that an ER-MP58-positive cell subpopulation of GM-CFCs proliferates in response to M-CSF, differentiates into preosteoclasts which fuse with each other to develop into mature osteoclasts.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8929623

Source DB:  PubMed          Journal:  J Submicrosc Cytol Pathol        ISSN: 1122-9497


  7 in total

Review 1.  Pathogenesis of postmenopausal osteoporosis.

Authors:  L G Raisz
Journal:  Rev Endocr Metab Disord       Date:  2001-01       Impact factor: 6.514

2.  Deficiency of SHP-1 protein-tyrosine phosphatase activity results in heightened osteoclast function and decreased bone density.

Authors:  S Umeda; W G Beamer; K Takagi; M Naito; S Hayashi; H Yonemitsu; T Yi; L D Shultz
Journal:  Am J Pathol       Date:  1999-07       Impact factor: 4.307

3.  Development of mature and functional human myeloid subsets in hematopoietic stem cell-engrafted NOD/SCID/IL2rγKO mice.

Authors:  Satoshi Tanaka; Yoriko Saito; Jun Kunisawa; Yosuke Kurashima; Taichi Wake; Nahoko Suzuki; Leonard D Shultz; Hiroshi Kiyono; Fumihiko Ishikawa
Journal:  J Immunol       Date:  2012-05-18       Impact factor: 5.422

4.  Effects of macrophage colony-stimulating factor on macrophages and their related cell populations in the osteopetrosis mouse defective in production of functional macrophage colony-stimulating factor protein.

Authors:  S Umeda; K Takahashi; L D Shultz; M Naito; K Takagi
Journal:  Am J Pathol       Date:  1996-08       Impact factor: 4.307

5.  Granulocyte/macrophage colony-stimulating factor and interleukin-3 correct osteopetrosis in mice with osteopetrosis mutation.

Authors:  Y Y Myint; K Miyakawa; M Naito; L D Shultz; Y Oike; K Yamamura; K Takahashi
Journal:  Am J Pathol       Date:  1999-02       Impact factor: 4.307

Review 6.  Role of Biomolecules in Osteoclasts and Their Therapeutic Potential for Osteoporosis.

Authors:  Xin Zhao; Suryaji Patil; Fang Xu; Xiao Lin; Airong Qian
Journal:  Biomolecules       Date:  2021-05-17

7.  A sequential culture approach to study osteoclast differentiation from nonadherent porcine bone marrow cells.

Authors:  B A Scheven; J S Milne; S P Robins
Journal:  In Vitro Cell Dev Biol Anim       Date:  1998 Jul-Aug       Impact factor: 2.723

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.